| 總結: | Objective: In this study, it was aimed to investigate the presence of blaOXA-48- like, blaCTX-M-15, blaNDM-1 genes and susceptibility to apramycin of carbapenemresistant Klebsiella pneumoniae isolates isolated from various clinical samples. Material and Methods: Twelve multiple resistant K. pneumoniae isolates isolated from various clinical samples of hospitalized patients in Istanbul Faculty of Medicine Hospital between June and September 2020 were included in the study. The minimum inhibitory concentration (MIC) values for imipenem, meroperem, ertapenem and apramycin in these isolates were determined using the broth microdilution method according to EUCAST recommendations. The antibiotic concentrations were determined as <0.016-256 µg/mL, including the clinical breakpoints of EUCAST (imipenem, meropenem, ertapenem) and NARMS (apramycin). The presence of blaOXA-48, blaNDM-1, blaCTX-M-15 genes in K. pneumoniae isolates was investigated using the classical polymerase chain reaction (PCR) method. Results: The blaOXA-48-like and blaCTX-M-15 genes were detected in all isolates (n=12) of K. pneumoniae resistant to carbapenems, and the blaNDM-1 gene was found in one (8.33%). All isolates were found to be resistant to ertapenem, 91.7% of meropenem, 58.3% of imipenem. All isolates were determined as being susceptible to apramycin. The MIC values were detected between 4-256 µg/mL for ertapenem, 0.5-64 µg/mL for meropenem, 0.5-128 µg/mL for imipenem, and <0.016-2 µg/mL for apramycin. Conclusion: The detection of low MIC values for apramycin in K. pneumoniae isolates suggests that it may be an alternative treatment agent for isolates resistant to carbapenems or all antibiotics. Therefore, there is a need for more comprehensive studies on the clinical use of apramycin.
|
|---|
